ImmuPharma plc (LON:IMM – Get Free Report)’s stock price shot up 5.6% on Wednesday . The company traded as high as GBX 4.44 and last traded at GBX 4.44. 110,458 shares were traded during mid-day trading, a decline of 96% from the average session volume of 3,109,149 shares. The stock had previously closed at GBX 4.20.
ImmuPharma Stock Up 0.7%
The business has a 50-day simple moving average of GBX 5.03 and a two-hundred day simple moving average of GBX 6.68. The stock has a market capitalization of £26.20 million, a P/E ratio of -4.72 and a beta of 2.98.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
